By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TG Therapeutics, Inc. 

787 Seventh Avenue
48th Floor
New York  New York  10019  U.S.A.
Phone: 212-554-4484 Fax: 212-554-4531


SEARCH JOBS


Industry
Pharmaceutical






Company News
TG Therapeutics (TGTX) Announces Successful Outcome From The First Pre-Planned Interim Analysis By Independent DSMB Of The DLBCL Cohort In The UNITY-NHL Phase IIb Trial 8/10/2017 11:53:08 AM
TG Therapeutics (TGTX) Provides Business Update And Reports Second Quarter 2017 Financial Results 8/9/2017 1:01:20 PM
TG Therapeutics (TGTX) To Host Conference Call On Second Quarter 2017 Financial Results And Business Update 8/7/2017 12:04:55 PM
TG Therapeutics (TGTX) Announces Special Protocol Assessment (SPA) Agreement With The FDA For A Phase III Program Of TG-1101 (Ublituximab) For Patients With Multiple Sclerosis (MS) 8/1/2017 11:57:20 AM
TG Therapeutics (TGTX) Recaps Preliminary Results From Ongoing Phase II Study Of TG-1101 (Ublituximab) In Patients With Multiple Sclerosis At The 3rd Congress Of The European Academy Of Neurology 6/26/2017 12:14:55 PM
TG Therapeutics (TGTX) Recaps Data From Triple Combination Therapy Trials At The 22nd European Hematology Association Annual Congress 6/26/2017 11:15:47 AM
TG Therapeutics (TGTX) Recaps Positive Data From The Phase III GENUINE Trial And Data From The Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 14th International Conference On Malignant Lymphoma 6/16/2017 9:02:05 AM
TG Therapeutics (TGTX) Announces Follow-Up Data For Combination Of TGR-1202 (Umbralisib) Plus Ibrutinib In Patients With Relapsed Or Refractory CLL And MCL At The 14th International Conference On Malignant Lymphoma 6/14/2017 12:17:09 PM
TG Therapeutics (TGTX) Announces Follow-Up Data From The Chemo-Free Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 53rd Annual Meeting Of The ASCO 6/5/2017 11:53:40 AM
TG Therapeutics (TGTX) Announces Successful Outcome From Pre-Planned Interim Analysis By Independent DSMB In The UNITY-CLL Phase III Trial 5/23/2017 11:15:20 AM
12345678910...
//-->